204 results on '"Higgs, Richard E."'
Search Results
2. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Catalog
Books, media, physical & digital resources
3. Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
4. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19
5. SeedMatchR: Identify off-target effects mediated by siRNA seed regions in RNA-seq experiments
6. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
7. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
8. Assessment and Clinical Relevance of Serum IL-19 Levels in Psoriasis and Atopic Dermatitis Using a Sensitive and Specific Novel Immunoassay
9. Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma
10. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
11. The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination
12. The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
13. Additional file 1 of Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab
14. A Quantitative Tool to Distinguish Isobaric Leucine and Isoleucine Residues for Mass Spectrometry-Based De Novo Monoclonal Antibody Sequencing
15. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats
16. Structure-guided expansion of kinase fragment libraries driven by support vector machine models
17. The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination
18. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
19. Evaluating the performances of quantitative structure-retention relationship models with different sets of molecular descriptors and databases for high-performance liquid chromatography predictions
20. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
21. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
22. Proteomic Analysis of Demyelinated and Remyelinating Brain Tissue following Dietary Cuprizone Administration
23. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
24. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate‐to‐severe disease
25. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
26. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
27. From Ghrelin to Ghrelin's O-Acyl Transferase
28. Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials
29. Use of direct-infusion electrospray mass spectrometry to guide empirical development of improved conditions for expression of secondary metabolities from actinomycetes
30. Rapid method to estimate the presence of secondary metabolites in microbial extracts
31. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection
32. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
33. Tu1853 SUSTAINED REDUCTION OF IL-23 RELATED CYTOKINES IL-17A AND IL-22 IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS THROUGH WEEK 52
34. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients
35. O4 Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus
36. A method for quantitatively differentiating crude natural extracts using high-performance liquid chromatography-electrospray mass spectrometry
37. Kinomics—structural biology and chemogenomics of kinase inhibitors and targets
38. A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus
39. THU0212 BARICITINIB-ASSOCIATED CHANGES IN GLOBAL GENE EXPRESSION DURING A 24-WEEK PHASE 2 CLINICAL SLE TRIAL DESCRIBE A MECHANISM OF ACTION THROUGH INHIBITION OF JAK/STAT AND IFN RESPONSIVE GENE EXPRESSION
40. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk
41. Tu1712 – Reduction in Inflammatory Biomarkers in a Phase 2 Study of Mirikizumab in the Treatment of Patients with Moderatelyto-Severely Active Ulcerative Colitis
42. 185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial
43. Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice
44. An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies
45. Chapter Nine - From Ghrelin to Ghrelin's O-Acyl Transferase
46. Abstract 29: Concordance of somatic mutations found in primary tumors and plasma circulating-free DNA from early and late-stage colorectal cancer patients
47. Evaluation of the Relative Performance of Drug-Induced Skeletal Muscle Injury Biomarkers in Rats
48. Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
49. Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
50. Quantitative Proteomics via High Resolution MS Quantification: Capabilities and Limitations
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.